ロード中...
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Talimogene laherparepvec is a first-in-class intralesional oncolytic immunotherapy. In a recent Phase III trial (OPTiM), talimogene laherparepvec significantly improved durable response rate compared with subcutaneous granulocyte–macrophage colony-stimulating factor (GM-CSF). Overall response rate w...
保存先:
| 出版年: | Cancer Immunol Immunother |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Berlin Heidelberg
2017
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5445176/ https://ncbi.nlm.nih.gov/pubmed/28238174 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-017-1967-1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|